Ian Glaspole

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Talmadge E. King, Williamson Z. Bradford, Socorro Castro-Bernardini et al. · New England Journal of Medicine · 2014 · 3.9K citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial

Leona Dowman, Christine F. McDonald, Catherine J. Hill et al. · Thorax · 2017 · 274 citations · Full text

Medicine, Internal Medicine, Physical Activity +16

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON

Bruno Crestani, John T. Huggins, Mitchell Kaye et al. · The Lancet Respiratory Medicine · 2018 · 239 citations

Medicine, Clinical Sciences, Internal Medicine +6

Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry

Helen E. Jo, Ian Glaspole, Christopher Grainge et al. · European Respiratory Journal · 2017 · 236 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

Joshua J. Solomon, Sonye K. Danoff, Felix Woodhead et al. · The Lancet Respiratory Medicine · 2022 · 208 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8